tetano
Editor, Senior Moderator
Med Res Rev
. 2023 Mar 23.
doi: 10.1002/med.21951. Online ahead of print.
Use of baricitinib in treatment of COVID-19: a systematic review
Ananyan Sampath[SUP] 1 [/SUP], Aditya Banerjee[SUP] 1 [/SUP], Shubham Atal[SUP] 1 [/SUP], Ratinder Jhaj[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: To assess the role of baricitinib alone or in combination with other therapies as a treatment for patients with COVID-19.
Methods: Systematic literature search was conducted in the WHO COVID-19 coronavirus disease database to find clinical studies on use of baricitinib for treatment of COVID-19 between December 1, 2019 and September 30, 2021. Two independent set of reviewers identified the eligible studies fulfilling the inclusion criteria, relevant data was extracted and a qualitative synthesis of evidence performed. The risk of bias was evaluated with validated tools.
Results: A total of 267 articles were found to be eligible after primary screening of titles and abstracts. Following assessment of full texts, 19 studies were finally included for this systematic review, out of which 16 are observational, and 3 are interventional studies. Collating the results from these observational and interventional studies, baricitinib used as add-on to standard therapy, either alone or in combination with other drugs, was found to have favorable outcomes in hospitalized patients with moderate to severe COVID-19. Furthermore, ongoing trials indicate that the drug is being extensively studied across the world for its safety and efficacy in COVID-19.
Conclusion: Baricitinib significantly improves clinical outcomes in hospitalized patients with COVID-19 pneumonia, and further evidence will establish the drug as a standard treatment among such patients.
Keywords: COVID-19; JAK kinase inhibitor; SARS-Cov-2; baricitinib; clinical outcome; mortality.
. 2023 Mar 23.
doi: 10.1002/med.21951. Online ahead of print.
Use of baricitinib in treatment of COVID-19: a systematic review
Ananyan Sampath[SUP] 1 [/SUP], Aditya Banerjee[SUP] 1 [/SUP], Shubham Atal[SUP] 1 [/SUP], Ratinder Jhaj[SUP] 1 [/SUP]
Affiliations
- PMID: 36951224
- DOI: 10.1002/med.21951
Abstract
Objective: To assess the role of baricitinib alone or in combination with other therapies as a treatment for patients with COVID-19.
Methods: Systematic literature search was conducted in the WHO COVID-19 coronavirus disease database to find clinical studies on use of baricitinib for treatment of COVID-19 between December 1, 2019 and September 30, 2021. Two independent set of reviewers identified the eligible studies fulfilling the inclusion criteria, relevant data was extracted and a qualitative synthesis of evidence performed. The risk of bias was evaluated with validated tools.
Results: A total of 267 articles were found to be eligible after primary screening of titles and abstracts. Following assessment of full texts, 19 studies were finally included for this systematic review, out of which 16 are observational, and 3 are interventional studies. Collating the results from these observational and interventional studies, baricitinib used as add-on to standard therapy, either alone or in combination with other drugs, was found to have favorable outcomes in hospitalized patients with moderate to severe COVID-19. Furthermore, ongoing trials indicate that the drug is being extensively studied across the world for its safety and efficacy in COVID-19.
Conclusion: Baricitinib significantly improves clinical outcomes in hospitalized patients with COVID-19 pneumonia, and further evidence will establish the drug as a standard treatment among such patients.
Keywords: COVID-19; JAK kinase inhibitor; SARS-Cov-2; baricitinib; clinical outcome; mortality.